Linked Life Data

10605321

Source:http://linkedlifedata.com/resource/pubmed/id/10605321

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
10
pubmed:dateCreated
2000-1-11
pubmed:abstractText
Lercanidipine (Zanidip) is a new calcium antagonist belonging to the dihydropyridine family suitable for the first-line treatment of hypertension. This molecule displays a high specificity and selectivity for vascular smooth muscle cells and has, in spite of a short plasma half-life, a long duration of action due to its liposolubility. The usual and once a day dose to treat high blood pressure of any grade is 10 mg, which if needed could be increased to 20 mg once a day. It has a gradual onset of effect on blood pressure, thus leading to a good tolerability and hopefully a better compliance in the treatment of hypertension. No adaptation of the dose is needed in older patients or in patients with moderate renal or liver impairment.
pubmed:language
fre
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Oct
pubmed:issn
0370-629X
pubmed:author
pubmed:issnType
Print
pubmed:volume
54
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
832-4
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed:year
1999
pubmed:articleTitle
[Pharma-clinics. Drug of the month. Lercanidipine (Zanidip)].
pubmed:affiliation
Département de Médecine Interne, C.H.U. Liège.
pubmed:publicationType
Journal Article, English Abstract